http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-100420-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-78 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D411-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 |
| filingDate | 2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0220fd3dad38170a216573b77aa53fae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b648f8c3ad2468c6bccf6b916c259dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b2359a6a08ec13d6eb7b3d042241876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da8f5417f2a918b9f6c508e75de3dfd4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f25bdbd85cde0430aabab141eadabc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1354a322a0423d072292771643bf7d80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c076aa9123050ba50e604a50ee02b511 |
| publicationDate | 2016-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-100420-A1 |
| titleOfInvention | BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM |
| abstract | The present application refers to a bicyclic derivative that has inhibitory activity against transporters related to sodium glucose (SGLTs) present in the intestines and kidneys, or one of its salts, isomers, hydrates or solvates acceptable from the point of pharmaceutical view, and a pharmaceutical composition that includes them as active ingredient, that effectively inhibit the activity of SGLT, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes that includes insulin-dependent diabetes ( Type I diabetes mellitus) and non-insulin dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity. Claim 1: A bicyclic derivative represented by formula (1), or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein A is -O- or -CH₂-; Ring B is selected from the group consisting of structural formulas (2), (3) and (4); R¹, R², and R³ are each independently H, halogen, hydroxy, C₁₋₈ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, or C₃₋₆ cycloalkyloxy, in where C₁₋₈ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, and C₃₋₆ cycloalkyloxy can each be independently substituted with 1 to 5 fluoro groups, C₁₋ alkyl ₄, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, 3 to 6 membered heterocycloalkyloxy, or C alqu alkylsulfonyl groups, wherein the C₁₋₈ alkoxy can be substituted with one to two C₁₋₈ alkoxy or C₃₋₆ cycloalkyloxy groups; R¹ and R² substituted on two adjacent carbon atoms can be joined to form a C₃₋₅ alkylene bridge, where one to two methylene groups on the C₃₋₅ alkylene bridge can each be independently replaced with -O-, -S-, -S (= O) -, -S (= O) ₂-, -C (= O) -, or -N (-R⁴) -, and the unsubstituted methylene groups can each be independently substituted with 1 up to 4 halogens or methyl groups; R⁴ is H or benzyl; and the heterocycloalkyl includes at least one heteroatom selected from the group consisting of O, N, and S. |
| priorityDate | 2014-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.